The Lancet Oncology
@thelancetoncol
The Lancet Oncology is the global leader in clinical oncology publishing peer-reviewed research and reviews, comment, news, and Commissions. IF=41.6
ID: 50265238
http://www.thelancet.com/journals/lanonc 24-06-2009 09:52:31
10,10K Tweet
58,58K Takipçi
431 Takip Edilen
Presented at #ESMO22 ESMO - Eur. Oncology, now in our Oct issue: interim analysis of PEARLS/KEYNOTE-091: #pembrolizumab vs placebo as #adjuvant therapy for completely resected stage IB–IIIA non-small-cell #lungcancer #NSCLC thelancet.com/journals/lanon…